Evidence map›Paper›PMID 24077280›Full record

ArticleOncogene2014

Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression.

F Bengsch, A Buck, S C Günther, J R Seiz, M Tacke, D Pfeifer, D von Elverfeldt, L Sevenich, L E Hillebrand, U Kern and 4 more

Abstract read
In one paragraph

Article in Oncogene, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 105 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

F Bengsch1] Institute of Molecular Medicine and Cell Research, Albert-Ludwigs-University Freiburg, Freiburg, Germany [2] Spemann Graduate School of Biology and Medicine, Albert-Ludwigs-University Freiburg, Freiburg, Germany [3] Faculty of Biology, Albert-Ludwigs-University Freiburg, Freiburg, Germany.
A BuckInstitute of Molecular Medicine and Cell Research, Albert-Ludwigs-University Freiburg, Freiburg, Germany.
S C GüntherInstitute of Molecular Medicine and Cell Research, Albert-Ludwigs-University Freiburg, Freiburg, Germany.
J R SeizInstitute of Molecular Medicine and Cell Research, Albert-Ludwigs-University Freiburg, Freiburg, Germany.
M TackeInstitute of Molecular Medicine and Cell Research, Albert-Ludwigs-University Freiburg, Freiburg, Germany.
D PfeiferDepartment of Hematology/Oncology, Genomics Core Lab, University Medical Center, Freiburg, Germany.
D von ElverfeldtDepartment of Radiology, Medical Physics, University Medical Center, Freiburg, Germany.
L Sevenich1] Institute of Molecular Medicine and Cell Research, Albert-Ludwigs-University Freiburg, Freiburg, Germany [2].
L E Hillebrand1] Institute of Molecular Medicine and Cell Research, Albert-Ludwigs-University Freiburg, Freiburg, Germany [2] Faculty of Biology, Albert-Ludwigs-University Freiburg, Freiburg, Germany [3] BIOSS Centre for Biological Signalling Studies, Freiburg, Germany.
U Kern1] Institute of Molecular Medicine and Cell Research, Albert-Ludwigs-University Freiburg, Freiburg, Germany [2] Spemann Graduate School of Biology and Medicine, Albert-Ludwigs-University Freiburg, Freiburg, Germany [3] Faculty of Biology, Albert-Ludwigs-University Freiburg, Freiburg, Germany.
M SameniDepartment of Pharmacology, Wayne State University, Detroit, MI, USA.
C Peters1] Institute of Molecular Medicine and Cell Research, Albert-Ludwigs-University Freiburg, Freiburg, Germany [2] BIOSS Centre for Biological Signalling Studies, Freiburg, Germany.
B F Sloane1] Department of Pharmacology, Wayne State University, Detroit, MI, USA [2] Barbara Ann Carmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
T Reinheckel1] Institute of Molecular Medicine and Cell Research, Albert-Ludwigs-University Freiburg, Freiburg, Germany [2] BIOSS Centre for Biological Signalling Studies, Freiburg, Germany.
University of Freiburg · DEUniversity Medical Center Freiburg · DEWayne State University · US

Funding

Tumor Biology and Microenvironment (Program 1)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI PAUL M STEMMER · 1985 to 2026
$68.4M
Enhancing neoadjuvant chemotherpay responses with targeted T cellsR01CA140314 · NCI · WAYNE STATE UNIVERSITY · PI BEPLER, GEROLD · 2010 to 2015
$2.5M
NCI NIH HHS P30 CA022453NCI NIH HHS P30CA22453NCI NIH HHS R01 CA140314
6 · The paper itself

Abstract

The cysteine protease cathepsin B (CTSB) is frequently overexpressed in human breast cancer and correlated with a poor prognosis. Genetic deficiency or pharmacological inhibition of CTSB attenuates tumor growth, invasion and metastasis in mouse models of human cancers. CTSB is expressed in both cancer cells and cells of the tumor stroma, in particular in tumor-associated macrophages (TAM). In order to evaluate the impact of tumor- or stromal cell-derived CTSB on Polyoma Middle T (PyMT)-induced breast cancer progression, we used in vivo and in vitro approaches to induce human CTSB overexpression in PyMT cancer cells or stromal cells alone or in combination. Orthotopic transplantation experiments revealed that CTSB overexpression in cancer cells rather than in the stroma affects PyMT tumor progression. In 3D cultures, primary PyMT tumor cells showed higher extracellular matrix proteolysis and enhanced collective cell invasion when CTSB was overexpressed and proteolytically active. Coculture of PyMT cells with bone marrow-derived macrophages induced a TAM-like macrophage phenotype in vitro, and the presence of such M2-polarized macrophages in 3D cultures enhanced sprouting of tumor spheroids. We employed a doxycycline (DOX)-inducible CTSB expression system to selectively overexpress human CTSB either in cancer cells or in macrophages in 3D cocultures. Tumor spheroid invasiveness was only enhanced when CTSB was overexpressed in cancer cells, whereas CTSB expression in macrophages alone did not further promote invasiveness of tumor spheroids. We conclude that CTSB overexpression in the PyMT mouse model promotes tumor progression not by a stromal effect, but by a direct, cancer cell-inherent mode of action: CTSB overexpression renders the PyMT cancers more invasive by increasing proteolytic extracellular matrix protein degradation fostering collective cell invasion into adjacent tissue.

Indexed as

AnimalsAntigens, Polyomavirus TransformingBreast NeoplasmsCarcinoma, Ductal, BreastCathepsin BDisease ProgressionDoxycyclineExtracellular Matrix ProteinsFemaleGene Expression Regulation, NeoplasticHumansMacrophagesMammary Neoplasms, ExperimentalMiceMice, TransgenicStromal CellsAntigens, Polyomavirus TransformingCathepsin BCTSB protein, humanDoxycyclineExtracellular Matrix Proteins

Identifiers

PMID24077280
PMCPMC4139469
OpenAlexW1980239925

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.